Trial · NCT02450552
Results by group177
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 177
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Short-interval Intracortical Inhibition (SICI) Measured by Transcranial Magnetic Stimulation (TMS) | Oral Ezogabine 900 mg/Day | Screening | 1.180 | Standard Deviation 1.108 | Unitless |
| Change in Short-interval Intracortical Inhibition (SICI) Measured by Transcranial Magnetic Stimulation (TMS) | Oral Ezogabine 600 mg/Day | Screening | 0.965 | Standard Deviation 1.302 | Unitless |
| Change in Short-interval Intracortical Inhibition (SICI) Measured by Transcranial Magnetic Stimulation (TMS) | Placebo | Screening | 0.784 | Standard Deviation 0.560 | Unitless |
| Change in Short-interval Intracortical Inhibition (SICI) Measured by Transcranial Magnetic Stimulation (TMS) | Oral Ezogabine 900 mg/Day | Baseline | 1.347 | Standard Deviation 1.662 | Unitless |
| Change in Short-interval Intracortical Inhibition (SICI) Measured by Transcranial Magnetic Stimulation (TMS) | Oral Ezogabine 600 mg/Day | Baseline | 0.952 | Standard Deviation 1.138 | Unitless |
| Change in Short-interval Intracortical Inhibition (SICI) Measured by Transcranial Magnetic Stimulation (TMS) | Placebo | Baseline | 0.755 | Standard Deviation 0.539 | Unitless |
| Change in Short-interval Intracortical Inhibition (SICI) Measured by Transcranial Magnetic Stimulation (TMS) | Oral Ezogabine 900 mg/Day | Week 6 | 1.100 | Standard Deviation 1.066 | Unitless |
| Change in Short-interval Intracortical Inhibition (SICI) Measured by Transcranial Magnetic Stimulation (TMS) | Oral Ezogabine 600 mg/Day | Week 6 | 0.675 | Standard Deviation 0.613 | Unitless |
| Change in Short-interval Intracortical Inhibition (SICI) Measured by Transcranial Magnetic Stimulation (TMS) | Placebo | Week 6 | 0.777 | Standard Deviation 0.442 | Unitless |
| Change in Short-interval Intracortical Inhibition (SICI) Measured by Transcranial Magnetic Stimulation (TMS) | Oral Ezogabine 900 mg/Day | Week 8 | 0.948 | Standard Deviation 1.169 | Unitless |
| Change in Short-interval Intracortical Inhibition (SICI) Measured by Transcranial Magnetic Stimulation (TMS) | Oral Ezogabine 600 mg/Day | Week 8 | 0.617 | Standard Deviation 0.455 | Unitless |
| Change in Short-interval Intracortical Inhibition (SICI) Measured by Transcranial Magnetic Stimulation (TMS) | Placebo | Week 8 | 0.834 | Standard Deviation 0.488 | Unitless |
| Change in Resting Motor Evoked Potential (MEP) Threshold (Prespecified Secondary Outcome of Primary Importance) | Oral Ezogabine 900 mg/Day | Screening | 51.250 | Standard Deviation 14.379 | percentage of the maximum output |
| Change in Resting Motor Evoked Potential (MEP) Threshold (Prespecified Secondary Outcome of Primary Importance) | Oral Ezogabine 600 mg/Day | Screening | 52.000 | Standard Deviation 11.480 | percentage of the maximum output |
| Change in Resting Motor Evoked Potential (MEP) Threshold (Prespecified Secondary Outcome of Primary Importance) | Placebo | Screening | 56.308 | Standard Deviation 13.804 | percentage of the maximum output |
| Change in Resting Motor Evoked Potential (MEP) Threshold (Prespecified Secondary Outcome of Primary Importance) | Oral Ezogabine 900 mg/Day | Baseline | 48.385 | Standard Deviation 14.373 | percentage of the maximum output |
| Change in Resting Motor Evoked Potential (MEP) Threshold (Prespecified Secondary Outcome of Primary Importance) | Oral Ezogabine 600 mg/Day | Baseline | 54.250 | Standard Deviation 11.018 | percentage of the maximum output |
| Change in Resting Motor Evoked Potential (MEP) Threshold (Prespecified Secondary Outcome of Primary Importance) | Placebo | Baseline | 57.231 | Standard Deviation 13.498 | percentage of the maximum output |
| Change in Resting Motor Evoked Potential (MEP) Threshold (Prespecified Secondary Outcome of Primary Importance) | Oral Ezogabine 900 mg/Day | Week 6 | 50.111 | Standard Deviation 14.066 | percentage of the maximum output |
| Change in Resting Motor Evoked Potential (MEP) Threshold (Prespecified Secondary Outcome of Primary Importance) | Oral Ezogabine 600 mg/Day | Week 6 | 57.583 | Standard Deviation 15.365 | percentage of the maximum output |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02450552/results